Financials data is unavailable for this security.
View more
Year on year ChengDu Sheng Nuo Biotec Co Ltd grew revenues 9.93% from 395.72m to 435.02m while net income improved 9.08% from 64.48m to 70.34m.
| Gross margin | 60.50% |
|---|---|
| Net profit margin | 15.63% |
| Operating margin | 17.71% |
| Return on assets | 5.28% |
|---|---|
| Return on equity | 8.42% |
| Return on investment | 6.86% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at ChengDu Sheng Nuo Biotec Co Ltd fell by 154.27m. Cash Flow from Financing totalled 129.75m or 29.83% of revenues. In addition the company generated 84.78m in cash from operations while cash used for investing totalled 369.31m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 7.88 |
|---|---|
| Tangible book value per share | 7.40 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.48 |
|---|---|
| Quick ratio | 0.9354 |
| Total debt/total equity | 0.4544 |
|---|---|
| Total debt/total capital | 0.3124 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 12.00% and 9.07%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.53% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 31.12% |
| EPS growth(5 years) | 18.69 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.28 |
More ▼
